Company
Every investor coverage indicates participated in a round Savencia raised.
Companies Savencia acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Savencia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian food-tech firm All G has launched a low-iron, fermentation-derived lactoferrin in the US, producing multiple tonnes yearly via a Chinese manufacturer, with European capacity and a human-equivalent version planned.
Precision fermentation startup All G banked A$10 million through a convertible note and teamed up with French dairy ingredients maker Armor Protéines to sell lactoferrin, targeting a first product launch in early 2026.